View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 4, 2011

Exelixis to commence prostate cancer drug trial

Exelixis has announced that it will begin the pivotal Phase III '306 trial of cabozantinib in patients with metastatic castration-resistant prostate cancer by the end of 2011.

Exelixis has announced that it will begin the pivotal Phase III ‘306 trial of cabozantinib in patients with metastatic castration-resistant prostate cancer by the end of 2011.

The double-blind ‘306 trial is expected to enrol 246 CRPC patients, who will be randomised 1:1 to receive either cabozantinib or mitoxantrone / prednisone.

The alleviation of bone pain will be the primary endpoint of the study, while secondary endpoints include overall survival rate and bone scan response.

An earlier Phase II trial with cabozantinib demonstrated favourable effects on bone and soft tissue lesions, and in the relief of bone metastasis-related pain in castration-resistant prostate cancer patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena